CFO
BNTX icon

CVA Family Office’s BioNTech BNTX Stock Holding History

CVA Family Office’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12
Closed -$964 – 1281
2024
Q2 		$964 Buy
12
+1
+9% +$91 ﹤0.01% 1081
2024
Q1 		$1.01K Sell
11
-9
-45% -$863 ﹤0.01% 999
2023
Q4 		$2.11K Buy
+20
New +$2.02K ﹤0.01% 905

Other funds holding BNTX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Flossbach Von Storch
Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CVA Family Office's BNTX Position: Q3 2024 in Review

CVA Family Office sold out of BioNTech (BNTX) in Q3 2024, closing a stake of 12 shares — an estimated $964 sold.

CVA Family Office first reported a position in BNTX in Q4 2023 and held it in 3 quarters. The position peaked at $2.11K in Q4 2023. 296 funds tracked by Wall St. Rank hold BNTX as of Q3 2024.

  • CVA Family Office reported no remaining BioNTech position as of Q3 2024 after selling out during the quarter.
  • CVA Family Office sold 12 BioNTech shares in Q3 2024, an estimated $964.
  • CVA Family Office first reported a position in BioNTech in Q4 2023 and held it in 3 quarters.
  • CVA Family Office's BioNTech position peaked at $2.11K in Q4 2023.
  • 296 funds tracked by Wall St. Rank held BioNTech as of Q3 2024.

Based on CVA Family Office's 13F filing for Q3 2024, filed 10 Oct 2024.